Global Hypertrophic and Keloid Scar Therapy Market Insights and Forecast to 2028

The scar is elevated above the skin and remains hyperemic. Excessive fibrous tissue is classified as either a keloid or a hypertrophic scar. Kischer and Brody declared the collagen nodule to be the identifying structural unit of hypertrophic scars and keloids.
Market Analysis and Insights: Global Hypertrophic and Keloid Scar Therapy Market
Due to the COVID-19 pandemic, the global Hypertrophic and Keloid Scar Therapy market size is estimated to be worth US$ 7370.6 million in 2022 and is forecast to a readjusted size of US$ 11390 million by 2028 with a CAGR of 7.5% during the review period. Fully considering the economic change by this health crisis, Topical Products accounting for % of the Hypertrophic and Keloid Scar Therapy global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospitals segment is altered to an % CAGR throughout this forecast period.
China Hypertrophic and Keloid Scar Therapy market size is valued at US$ million in 2021, while the US and Europe Hypertrophic and Keloid Scar Therapy are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Hypertrophic and Keloid Scar Therapy landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Hypertrophic and Keloid Scar Therapy include Smith & Nephew, Enaltus, Merz, Lumenis, Sonoma Pharmaceuticals, Cynosure, Scar Heal, Mölnlycke Health and Perrigo, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Hypertrophic and Keloid Scar Therapy Scope and Segment
Hypertrophic and Keloid Scar Therapy market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Hypertrophic and Keloid Scar Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Topical Products
Laser Products
Injectable
Others
Segment by Application
Hospitals
Clinics
Others
By Company
Smith & Nephew
Enaltus
Merz
Lumenis
Sonoma Pharmaceuticals
Cynosure
Scar Heal
Mölnlycke Health
Perrigo
NewMedical Technology
Suneva Medical
Pacific World
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E